Safety of Romiplostim (Nplate®) Following UCBT

Inclusion Criteria

• •Any patient who has undergone a single or double umbilical cord blood transplant (UCBT) except those with primary myelofibrosis.
• •* Those with acute leukemia must be in remission at the time of transplant
• •Must have achieved neutrophil engraftment (defined as an ANC \>500 for three consecutive days) and be off daily G-CSF prior to starting romiplostim. Intermittent G-CSF is allowed.
• •Failure to achieve platelet engraftment (defined as platelet count ≥20x10\^9/L on 3 consecutive measurements without transfusion for 7 days) by day +28 post UCBT
• •Between day +28 and day +42 status post myeloablative or nonmyeloablative UCBT (single or double cord blood transplant)
• •Age ≥ 18 years
• •Adequate organ function within 7 days of enrollment defined as:
• •* Creatinine: ≤ 2.0 mg/dL
• •* Hepatic: SGOT and SGPT \< 5 x upper limit of institutional normal (ULN)
• •Women of child bearing potential agree to use effective contraception during therapy and for 4 months after completion of therapy
• •Voluntary written consent